Phase I and pharmacokinetic study of LY293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor and peroxisome proliferator activated receptor-gamma agonist (PPAR gamma) Meeting Abstract

  

Authors:	Budman, D. R.; Schwartz, G. K.; Endres, S.; Welch, M.; O'reilly, E.; Barile-Thiem, B.; Brail, L. H.; De Alwis, D. P.; Cleverly, A.; Weitzman, A.
Abstract Title:	Phase I and pharmacokinetic study of LY293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor and peroxisome proliferator activated receptor-gamma agonist (PPAR gamma)
Meeting Title:	14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Journal Title:	European Journal of Cancer
Volume:	38
Issue:	Suppl. 7
Meeting Dates:	2002 Nov 19-22
Meeting Location:	Frankfurt, Germany
ISSN:	0959-8049
Publisher:	Elsevier Inc.
Date Published:	2002-11-01
Start Page:	S89
Language:	English
ACCESSION:	WOS:000179895700292
PROVIDER:	wos
DOI:	10.1016/S0959-8049(02)80941-8
PUBMED:	12526123
Notes:	Meeting Abstract: 290 -- 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics -- NOV 19-22, 2002 -- FRANKFURT, GERMANY -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/71823